# 体外诊断质量控制市场

> IVD质量控制市场研究报告按应用（临床诊断、血液检测、微生物学、分子诊断、实验室质量控制）、按产品类型（控制血清、控制血浆、控制尿液、血气控制、凝血控制）、按最终用户（医院、诊断实验室、研究实验室、制药公司、血库）、按技术（化学、免疫测定、核酸扩增、质谱、微阵列）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.71%
- **2024:** $ 4.73 Billion
- **2025:** $ 4.9 Billion
- **2035:** $ 7.06 Billion
- **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Thermo Fisher Scientific (US), bioMerieux (FR), Ortho Clinical Diagnostics (US), Danaher Corporation (US), Sysmex Corporation (JP), Hologic, Inc. (US)

**Report ID:** MRFR/HC/30925-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/in-vitro-diagnostics-quality-control-market-32725

---

## Market Summary

## **IVD Quality Control Market Overview**

As per MRFR analysis, the In Vitro Diagnostics Quality Control Market Size was estimated at 4.73 (USD Billion) in 2024. The In Vitro Diagnostics Quality Control Market Industry is expected to grow from 4.91 (USD Billion) in 2025 to 6.81 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.71% during the forecast period (2025 - 2034).

## **Key IVD Quality Control Market Trends Highlighted**

The IVD Quality Control Market is witnessing significant growth driven by the increasing demand for accurate diagnostic testing. Key market drivers include the rise in chronic diseases and the need for early detection, which push healthcare providers to adopt stringent quality control measures. Furthermore, advancements in technology, such as automation and the integration of digital solutions, enhance the efficiency and reliability of in-vitro diagnostics. This growing emphasis on quality assurance in laboratories is further supported by regulatory requirements that seek to ensure patient safety and improve testing outcomes. There are numerous opportunities to be explored in this evolving market.

The expansion of personalized medicine presents a unique chance for companies to develop tailored quality control solutions that meet specific diagnostic needs. Additionally, as emerging economies invest in healthcare infrastructure, they create a demand for robust quality control processes in laboratories. This includes training and education programs focused on maintaining quality standards. The increasing focus on point-of-care testing also opens avenues for IVD quality control, allowing for faster and more accessible diagnostics while still ensuring reliability. Trends in recent times highlight the growing integration of quality control systems with laboratory information management systems (LIMS) to streamline operations.

Moreover, there is a notable shift toward the utilization of real-time data analytics to monitor quality control processes continuously, enabling quicker adjustments when needed. The rise of telemedicine and remote diagnostics during the recent years has also necessitated more robust quality control frameworks to support accurate remote testing. These trends indicate a move toward a more connected and efficient approach to quality control in the IVD sector, fostering an environment where accurate diagnostics can be achieved consistently and swiftly.

Source** Primary Research, Secondary Research, MRFR Database and Analyst Review**

## **IVD Quality Control Market Drivers**

### **Increasing Demand for Accurate Diagnostics**

The IVD Quality Control Market Industry is experiencing significant growth driven by the rising demand for accurate and reliable diagnostic tests. As healthcare systems around the world strive to improve patient outcomes, the necessity for quality control in in vitro diagnostics (IVD) has become paramount. Patients and healthcare providers are increasingly seeking tests that produce consistent and precise results, which not only help in making informed clinical decisions but also enhance overall healthcare quality. This demand is further fueled by the ongoing advancements in diagnostic technologies, including molecular diagnostics, point-of-care testing, and automated laboratory systems.

As a result, the need for stringent quality control measures is growing, ensuring that diagnostic products meet regulatory standards and fulfill the expectations of both clinicians and patients. Furthermore, as the healthcare landscape evolves with the rise of personalized medicine, the importance of reliable diagnostic tools is underscored, driving the continual investment in IVD quality control measures.By assuring the accuracy and reliability of tests, manufacturers can enhance their credibility in the marketplace, thereby encouraging wider adoption and further bolstering growth in the IVD Quality Control Market Industry.

### **Regulatory Compliance and Standards**

The regulatory landscape surrounding in vitro diagnostics is becoming increasingly stringent, requiring manufacturers to adhere to established quality standards. Compliance with these regulations not only ensures the safety and efficacy of diagnostic products but also contributes to the growth of the IVD Quality Control Market Industry. The implementation of quality control protocols helps manufacturers meet regulatory requirements, thereby minimizing the risk of costly recalls or legal issues.Additionally, as agencies worldwide continue to update guidelines and requirements, investment in quality control processes becomes essential to maintaining market competitiveness.

### **Technological Advancements in Diagnostic Tools**

The rapid advancement of technology in the healthcare sector, particularly in diagnostic tools, is propelling the IVD Quality Control Market Industry. Innovations such as automated systems, artificial intelligence in diagnostics, and next-generation sequencing have transformed traditional diagnostic methodologies. These technologies not only enhance the speed and efficiency of diagnostic procedures but also improve the accuracy of results. As technology continues to evolve, the need for robust quality control mechanisms becomes critical, reinforcing the importance of maintaining high standards in the IVD market.

## **IVD Quality Control Market Segment Insights**

### **IVD Quality Control Market Application Insights**

The IVD Quality Control Market is projected to witness a robust growth trajectory, especially within the Application segment, as key areas like Clinical Diagnostics, Blood Testing, Microbiology Testing, Molecular Diagnostics, and Quality Control in Laboratories become increasingly significant in healthcare. In 2023, the market was valued at around 4.4 USD Billion, demonstrating the rising demand for reliable quality control measures.

The Clinical Diagnostics area plays a pivotal role, commanding a market value of 1.5 USD Billion in 2023, with its significance underscored by the increasing focus on disease detection and patient management.Blood Testing, with a market value of 1.0 USD Billion, is another major player, given its essential function in transfusion medicine and the growing prevalence of blood disorders.

 Microbiology, valued at 0.8 USD Billion, functions as a critical field in identifying infectious diseases, reflecting the necessity for effective quality control in laboratory settings. Meanwhile, Molecular Diagnostics contributes significantly as well, valued at 1.0 USD Billion, driven by innovations in genetic testing and the demand for precision medicine, which continues to expand as society leans towards advanced healthcare solutions.Quality Control in Laboratories, although smaller in scale at 0.1 USD Billion, is essential for maintaining operational standards and ensuring the accuracy of test results.

These diverse segments together shape the market dynamics, influenced by trends such as technological advancements, the growing incidence of chronic diseases, and the urgent need for accurate diagnostic tools. However, the market does face challenges, such as stringent regulations and the high costs associated with quality control processes. 

Despite these obstacles, opportunities remain abundant, particularly in the development of innovative quality control products and services that can improve diagnostic accuracy and operational efficiency in laboratories.The overall IVD Quality Control Market data indicates a healthy expansion ahead, emphasizing the significance of each application area within the healthcare system as it adapts to evolving demands and advancements. Such trends and figures reflect the more than promising market growth, with Clinical Diagnostics and Blood Testing taking substantial market shares, thereby highlighting the vital roles these applications play in enhancing patient care and disease management efforts across the globe.

The IVD Quality Control Market statistics reveal an industry that is not only expanding but diversifying, catering to the needs of various segments while addressing ongoing challenges with innovative solutions and strategies.

Source** Primary Research, Secondary Research, MRFR Database and Analyst Review**

### **IVD Quality Control Market Product Type Insights**

The IVD Quality Control Market was valued at 4.4 USD Billion in 2023, reflecting the growing importance of maintaining quality standards in laboratory diagnostics. Within this market, control sera, control plasma, control urine, control for blood gases, and control for coagulation play pivotal roles. Controlling sera and control plasma are particularly vital as they ensure accurate test results, aiding in disease diagnosis and monitoring. Control of urine is significant for various assays, especially in nephrology, while control for blood gases is crucial in critical care settings, as it helps manage respiratory and metabolic disorders.

Control for coagulation remains essential for anticoagulant therapy management and surgical procedures.

The diverse applications and critical necessity of these product types showcase their majority holding in the market, leading to steady market growth driven by advancements in IVD technology, increasing diagnostic testing rates, and the rising prevalence of chronic diseases. The IVD Quality Control Market data reflects a consistent demand as healthcare providers strive towards enhanced patient safety and effective diagnostics.

### **IVD Quality Control Market End User Insights**

The IVD Quality Control Market was valued at 4.4 USD Billion in 2023, with a significant focus on the End User segment, which includes hospitals, diagnostic laboratories, research laboratories, pharmaceutical companies, and blood banks. Hospitals play a crucial role in utilizing IVD quality control processes to ensure accurate diagnostics and patient safety. Diagnostic laboratories, often leading in market growth, emphasize the need for reliable quality control solutions to maintain their operational integrity. Research laboratories contribute to innovation within the sector, providing invaluable data that drives advancements in quality control methodologies.

Pharmaceutical companies increasingly depend on precise IVD testing for drug development and regulatory compliance, highlighting their significance in the market space. Blood banks also hold a critical position, as proper quality control is essential for safe blood supply. Overall, the IVD Quality Control Market segmentation reflects a dynamic interplay among these end users, each contributing to the efficiency and reliability of diagnostic processes, driving further enhancement in quality standards across the industry.

### **IVD Quality Control Market Technology Insights**

The IVD Quality Control Market, particularly within the Technology segment, is poised for notable progress as the market was valued at 4.4 billion USD in 2023 and is projected to grow steadily. This segment includes a range of technologies that play essential roles in diagnostic testing and quality management. Chemistry technologies are crucial as they enhance laboratory efficiency and reliability. Immunoassay technologies are significant due to their high sensitivity and specificity in detecting various analytes, which drives widespread adoption.Nucleic Acid Amplification technologies dominate in molecular diagnostics because of their ability to detect genetic material with high precision.

Mass Spectrometry is increasingly favored for its accuracy in complex biomarker detection, making it indispensable in advanced diagnostics. Microarray technologies offer significant advancements in high-throughput screening, allowing for comprehensive analyses in genomics and personalized medicine.

Collectively, these technologies contribute richly to the IVD Quality Control Market revenue, demonstrating strong synergy in improving patient outcomes while adhering to stringent regulatory standards.Market growth in this segment is propelled by increasing demand for accurate diagnostics, technological advancements, and a shift towards personalized medicine, while challenges include the need for continuous innovation and managing the costs associated with advanced testing technologies.

### **IVD Quality Control Market Regional Insights**

The IVD Quality Control Market exhibited a diverse regional segmentation, with North America leading the charge, generating a revenue of 1.8 USD Billion in 2023 and projected to grow to 2.5 USD Billion by 2032, primarily due to advanced healthcare infrastructure and a focus on diagnostics. Europe follows with a significant valuation of 1.2 USD Billion in 2023, increasing to 1.7 USD Billion by 2032, reflecting strong regulations and a growing demand for accurate diagnostics.

The APAC region, while smaller at 0.9 USD Billion in 2023, is expected to reach 1.2 USD Billion by 2032, driven by expanding healthcare investments and a rising population.Meanwhile, South America and MEA hold lower valuations at 0.3 USD Billion and 0.2 USD Billion, respectively, in 2023, with South America projected to grow to 0.4 USD Billion and MEA to 0.3 USD Billion by 2032, showcasing potential growth opportunities in these emerging markets. The majority holding in North America showcases technological advancements that dominate the market, while the growth in APAC illustrates an increasing focus on improving healthcare systems.

Overall, these insights provide a comprehensive view of the IVD Quality Control Market segmentation within regional boundaries.

Source** Primary Research, Secondary Research, MRFR Database and Analyst Review**

## **IVD Quality Control Market Key Players and Competitive Insights**

The IVD Quality Control Market is characterized by substantial competition among various key players, each aiming to innovate and deliver superior quality control solutions for in vitro diagnostics. As the demand for accurate and reliable diagnostic testing expands, companies are increasingly focused on enhancing their product offerings through research and development. The market is influenced by technological advancements, regulatory frameworks, and evolving healthcare needs, leading to a dynamic landscape where players must constantly adapt to maintain their competitive edge. Companies are also investing in strategic collaborations, mergers, and acquisitions to strengthen their market presence and expand their geographical reach. 

The integration of automation and digital technologies into quality control processes is becoming a critical differentiator among competitors, allowing for improved efficiency, accuracy, and compliance in laboratory settings.Siemens Healthineers holds a prominent position in the IVD Quality Control Market thanks to its extensive range of quality control products and solutions that cater to various diagnostic applications. The company's commitment to innovation and robust R&D has led to the development of highly accurate quality control systems that enhance laboratory performance and ensure reliable test results.

Siemens Healthineers leverages its strong reputation in the healthcare industry, built upon years of experience and expertise, to provide advanced analytics and tailored services that address the unique needs of laboratories worldwide. 

Its focus on customer-centric solutions and ability to deliver comprehensive service offerings provides a tangible advantage in a competitive market, enabling healthcare providers to achieve optimal operational efficiency and patient outcomes.Sysmex Corporation is another key player in the IVD Quality Control Market, known for its specialization in hematology and other diagnostic areas. The company combines cutting-edge technology with innovative quality control solutions that enhance laboratory workflows and ensure accurate diagnostic results.

Sysmex Corporation's strong commitment to research and development has led to the introduction of state-of-the-art quality control products that comply with international standards, thereby reinforcing its position in the market.

### **Key Companies in the IVD Quality Control Market Include**

- [Siemens Healthineers](https://www.siemens-healthineers.com/it/services/laboratory-diagnostics/service-and-support/quality-control-management)
- Sysmex Corporation
- Fujifilm
- Becton Dickinson
- Randox Laboratories
- Abbott Laboratories
- Danaher Corporation
- Hologic
- BioRad Laboratories
- Thermo Fisher Scientific
- Ortho Clinical Diagnostics
- Roche
- MilliporeSigma
- Parker Hannifin Corporation
- QA Labs

## In Vitro Diagnostics Quality Control Industry Developments

- **Q2 2024: Bio-Rad Launches New InteliQ Quality Controls for Immunoassay Testing** Bio-Rad Laboratories announced the launch of its InteliQ Immunoassay quality controls, designed to streamline laboratory workflow and improve the accuracy of immunoassay testing in clinical laboratories.
- **Q2 2024: Siemens Healthineers Receives FDA Clearance for Atellica Solution Quality Control Module** Siemens Healthineers received FDA clearance for its Atellica Solution Quality Control Module, which automates quality control processes for in vitro diagnostic testing, aiming to enhance laboratory efficiency and compliance.
- **Q2 2024: Roche Launches New Multi-Analyte Quality Control Panel for Molecular Diagnostics** Roche announced the commercial launch of a new multi-analyte quality control panel for molecular diagnostics, supporting laboratories in ensuring the reliability of their molecular testing platforms.
- **Q3 2024: Randox Laboratories Opens New Quality Control Manufacturing Facility in the UK** Randox Laboratories opened a new manufacturing facility dedicated to the production of in vitro diagnostics quality control materials, expanding its capacity to meet growing global demand.
- **Q3 2024: Thermo Fisher Scientific Announces Partnership with Beckman Coulter for Quality Control Solutions** Thermo Fisher Scientific entered into a partnership with Beckman Coulter to co-develop and distribute advanced quality control solutions for clinical laboratories, aiming to improve diagnostic accuracy and workflow.
- **Q3 2024: Bio-Techne Acquires QC Diagnostics to Expand Quality Control Portfolio** Bio-Techne completed the acquisition of QC Diagnostics, a company specializing in quality control materials for in vitro diagnostics, to broaden its product offerings and strengthen its market position.
- **Q4 2024: Abbott Receives CE Mark for Alinity Quality Control System** Abbott announced it has received CE Mark approval for its Alinity Quality Control System, enabling the company to market the product across the European Union for use in clinical laboratories.
- **Q4 2024: QuidelOrtho Launches New Quality Control Software for Point-of-Care Diagnostics** QuidelOrtho launched a new software platform designed to automate and manage quality control processes for its point-of-care diagnostic devices, aiming to enhance compliance and reduce manual errors.
- **Q1 2025: Bio-Rad Laboratories Appoints New Vice President of Quality Control Division** Bio-Rad Laboratories announced the appointment of a new Vice President to lead its Quality Control Division, focusing on strategic growth and innovation in the in vitro diagnostics quality control market.
- **Q1 2025: Siemens Healthineers Expands Quality Control Product Line with New Hematology Controls** Siemens Healthineers expanded its quality control product line by launching new hematology controls, designed to support laboratories in maintaining high standards of accuracy in blood analysis.
- **Q2 2025: Randox Laboratories Secures Major Contract to Supply Quality Control Materials to NHS** Randox Laboratories secured a significant contract to supply in vitro diagnostics quality control materials to the UK National Health Service, supporting the quality assurance of diagnostic testing across NHS laboratories.
- **Q2 2025: Roche Receives FDA Clearance for Next-Generation Quality Control Solution** Roche received FDA clearance for its next-generation quality control solution, designed to improve the reliability and efficiency of in vitro diagnostic testing in clinical laboratories.

## **IVD Quality Control Market Segmentation Insights**

### **IVD Quality Control Market Application Outlook**

- Clinical Diagnostics
- Blood Testing
- Microbiology
- Molecular Diagnostics
- Quality Control in Laboratories

### **IVD Quality Control Market Product Type Outlook**

- Control Sera
- Control Plasma
- Control Urine
- Control For Blood Gases
- Control For Coagulation

### **IVD Quality Control Market End User Outlook**

- Hospitals
- Diagnostic Laboratories
- Research Laboratories
- Pharmaceutical Companies
- Blood Banks

### **IVD Quality Control Market Technology Outlook**

- Chemistry
- Immunoassay
- Nucleic Acid Amplification
- Mass Spectrometry
- Microarray

### **IVD Quality Control Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 即时检测的增长

点对点检测（POCT）的增长正在成为体外诊断（IVD）质量控制市场的重要驱动力。POCT允许在患者护理现场快速获得诊断结果，这在各种医疗环境中越来越受到青睐。这一趋势在急救护理和偏远地区尤为相关，因为及时决策至关重要。随着对POCT需求的增加，确保这些检测的准确性和可靠性的严格质量控制措施的需求变得至关重要。IVD质量控制市场必须适应POCT带来的独特挑战，包括对便携式质量控制解决方案的需求。这一转变可能会刺激针对点对点应用的质量控制技术的创新和投资，从而扩大市场。

### 日益增加的监管要求

体外诊断（IVD）质量控制市场受到健康监管机构日益增加的监管要求的显著影响。监管机构不断更新指南，以确保体外诊断产品的安全性和有效性。制造商遵守这些法规对于维持市场准入和避免处罚至关重要。IVD质量控制市场必须适应这些不断变化的标准，这通常需要增强的质量控制措施。例如，引入更严格的质量保证协议可能会导致制造商的运营成本增加。然而，这也为增长提供了机会，因为投资于强大质量控制系统的公司可能会获得竞争优势。随着组织优先考虑合规性并寻求创新解决方案以满足监管要求，市场预计将扩大。

### 对准确诊断的需求上升

对准确诊断的日益重视是体外诊断（IVD）质量控制市场的主要驱动力。随着医疗系统努力改善患者的治疗结果，对可靠和精确的诊断工具的需求激增。这一需求反映在IVD市场的预计增长中，预计到2025年将达到约1000亿美元。IVD质量控制市场在确保诊断测试符合严格的准确性标准方面发挥着至关重要的作用，从而增强了医疗服务的整体可靠性。此外，慢性疾病的增加需要频繁检测，进一步推动了对IVD产品中强大质量控制措施的需求。因此，制造商越来越多地投资于质量控制解决方案，以保持合规并满足医疗提供者和患者的期望。

### 质量控制中的技术创新

技术创新正在显著影响体外诊断（IVD）质量控制市场。自动化、人工智能和数据分析的进步正在改变质量控制流程，使其更加高效和有效。例如，自动化质量控制系统可以减少人为错误并提高测试速度，这在临床环境中至关重要。人工智能在质量控制中的整合允许实时监控和预测分析，使得在问题出现之前能够采取主动措施。这种向技术驱动解决方案的转变预计将有助于IVD质量控制市场的增长，因为组织寻求利用这些创新来提高其运营效率和产品可靠性。因此，市场可能会见证新参与者的涌入，他们提供尖端的质量控制技术。

### 关注患者安全和质量保证

患者安全和质量保证的关注是体外诊断（IVD）质量控制市场的驱动力。随着医疗服务提供者越来越重视患者结果，对高质量诊断测试的需求也在加剧。这一关注体现在质量管理系统的日益采用上，这些系统确保IVD产品的可靠性。IVD质量控制市场正在响应这一趋势，开发与患者安全最佳实践相一致的全面质量保证协议。此外，质量保证的强调可能会导致制造商与医疗服务提供者之间的合作增加，促进持续改进的文化。因此，随着利益相关者认识到质量控制在提升患者安全和整体医疗质量中的重要性，市场预计将增长。

## Future Outlook

体外诊断（IVD）质量控制市场预计将在2024年至2035年间以3.71%的年均增长率增长，推动因素包括技术进步、监管变化以及对准确诊断的需求增加。

**New opportunities:**

- 为实验室开发集成质量控制软件解决方案。

到2035年，体外诊断质量控制市场预计将保持强劲，反映出持续的增长和创新。

## Segment Insights

### 按应用：临床诊断（最大）与血液检测（增长最快）

体外诊断（IVD）质量控制市场展示了多样化的应用格局，各个细分市场的市场份额分布显著。临床诊断占据最大份额，反映出对患者护理中准确可靠结果的持续需求。血液检测也是该市场的一个主要组成部分，受到血液相关疾病发生率上升和对精确诊断方法需求加大的推动。微生物检测和分子诊断虽然规模较小，但在应对特定医疗挑战方面发挥着重要作用，从而在市场中占据了自己的细分领域。
IVD质量控制市场的增长趋势有利于血液检测，成为增长最快的细分市场之一，推动因素包括技术进步和对个性化医疗的日益关注。实验室对合规性的推动增强了各个应用中质量控制解决方案的重要性。微生物检测和分子诊断由于在传染病检测和基因检测中的作用，正经历上升的势头。这一增长进一步得到了患者群体扩大和对诊断质量重要性认识加深的支持。

临床诊断（主导）与微生物检测（新兴）

临床诊断继续主导体外诊断（IVD）质量控制市场，因其在患者护理和诊断中的重要作用。该细分市场涵盖了一系列指导医疗决策的测试，确保测试过程的质量和可靠性。微生物检测虽然是新兴领域，但在感染控制和疾病管理中发挥着至关重要的作用。它专注于识别病原体和抗微生物药物的敏感性，随着抗生素耐药性上升，其相关性日益增强。这两个细分市场相辅相成，因为临床诊断中的质量控制提高了微生物检测的准确性。随着医疗环境的演变，临床诊断和微生物检测将继续适应，强调实验室服务的精确性和有效性。

### 按产品类型：对照血清（最大）与对照血浆（增长最快）

在体外诊断（IVD）质量控制市场中，控制血清在不同产品类型中占据最大的市场份额，反映了其在确保准确诊断测试中的重要作用。控制血浆紧随其后，成为一个重要组成部分，而控制尿液、血气控制和凝血控制则为满足各种诊断需求提供了多样化的产品组合。市场份额的分布表明实验室对控制血清的强烈偏好，突显了其在质量保证实践中的既定地位。
体外诊断（IVD）质量控制市场的增长趋势显示出对控制血浆的需求强劲增长，控制血浆正迅速成为增长最快的细分市场。这一增长可归因于诊断技术的进步和测试方法的日益复杂，这需要可靠的质量控制解决方案。此外，实验室对质量保证重要性的日益认识正在推动各种控制的采用，特别是控制尿液和凝血控制，这些在专业测试环境中正获得越来越多的关注。

对照血清（主导）与对照血浆（新兴）

控制血清在IVD质量控制市场中仍然是主导产品类型，因为它在验证各种诊断程序的测试结果方面有着悠久的应用。它为检测和面板测试提供了关键的参考点，确保结果的精确性和准确性。与此同时，控制血浆作为一个重要的竞争者正在崛起，受到临床检测创新和对血液学关注增加的推动。随着实验室寻求增强其质量保证协议，控制血清和控制血浆都准备继续增长，各自发挥独特的作用——控制血清作为常规检测的主要标准，而控制血浆则在专业和高通量诊断环境中扩大其影响力。

### 按最终用户：诊断实验室（最大）与医院（增长最快）

在体外诊断（IVD）质量控制市场中，终端用户之间的市场份额分布显著多样化。诊断实验室占据最大的市场份额，这归因于它们在进行广泛测试和确保众多诊断程序的质量保证方面的关键作用。医院紧随其后，利用先进的IVD技术来提升患者护理。研究实验室、制药公司和血液银行也有显著贡献，专注于专业应用，尽管它们的市场存在相对较小。

该细分市场的增长趋势显示，医院正成为增长最快的终端用户，受益于对医疗基础设施的投资增加和患者数量的上升。此外，诊断实验室继续扩大其市场份额，受到对精确诊断工具和质量控制措施需求的推动。研究实验室预计将稳步增长，因为它们专注于创新，而制药公司和血液银行则旨在增强其质量保证协议，以满足监管标准。

诊断实验室（主导）与医院（新兴）

诊断实验室由于其成熟的基础设施和测试服务的专业知识，成为体外诊断（IVD）质量控制市场的支柱，定位为主导力量。它们实施严格的质量控制措施，以保持准确性和可靠性，这对患者的结果至关重要。另一方面，医院在这个市场中迅速崛起，受到对诊断技术的投资增加和对以患者为中心的护理日益重视的推动。在医院环境中整合先进的IVD解决方案增强了它们提供快速可靠诊断的能力，反映出向更积极的医疗管理转变。随着医院在诊断过程中优先考虑质量控制，它们可能会经历显著增长，潜在地缩小与主导对手之间的差距。

### 按技术：免疫测定（最大）与质谱（增长最快）

体外诊断（IVD）质量控制市场在技术细分领域显示出多样化的分布，其中免疫测定因其在各种诊断应用中的广泛接受和实用性而处于领先地位。该细分市场之后是化学和核酸扩增，这些领域也对市场做出了重要贡献。尽管质谱和微阵列目前规模较小，但在各自的细分市场中正在取得显著进展，随着市场的发展，显示出良好的潜力。

免疫测定（主导）与质谱（新兴）

免疫测定技术在体外诊断（IVD）质量控制市场中脱颖而出，提供可靠且灵敏的各种生物标志物检测，从而确保质量控制过程的准确性。其确立的市场地位得益于在临床实验室中的广泛应用。相反，质谱技术正在迅速崛起，因其先进的分析能力、精确度以及处理复杂生物基质的能力而获得关注。虽然最初被视为小众，但其快速发展和适应性使其成为质量控制协议中的关键组成部分，对于满足对准确诊断解决方案日益增长的需求至关重要。

## Regional Market Share Analysis

IVD质量控制市场 展现出多样的区域细分，北美领先，2023年创造了18亿美元的收入，预计到2032年将增长至25亿美元，主要得益于先进的医疗基础设施和对诊断的关注。欧洲紧随其后，2023年估值为12亿美元，预计到2032年将增至17亿美元，反映出强有力的监管和对准确诊断的日益增长的需求。

亚太地区虽然在2023年较小，仅为9亿美元，预计到2032年将达到12亿美元，受益于不断扩大的医疗投资和人口增长。与此同时，南美和中东及非洲的估值较低，分别为3亿美元和2亿美元，预计南美到2032年将增长至4亿美元，中东及非洲将增长至3亿美元，展示出这些新兴市场的潜在增长机会。北美的主要市场份额展示了主导市场的技术进步，而亚太地区的增长则表明对改善医疗系统的日益关注。

总体而言，这些见解提供了IVD质量控制市场在区域边界内的全面视图。

来源** 初步研究、二次研究、MRFR数据库和分析师评审**

## Competitive Benchmarking

体外诊断（IVD）质量控制市场 的特点是各个主要参与者之间的激烈竞争，每个参与者都旨在创新并提供优质的体外诊断质量控制解决方案。随着对准确和可靠的诊断测试需求的增加，各公司越来越专注于通过研究和开发来增强其产品供应。市场受到技术进步、监管框架和不断变化的医疗需求的影响，形成了一个动态的格局，参与者必须不断适应以保持其竞争优势。公司还在战略合作、并购方面进行投资，以加强其市场存在并扩大其地理覆盖范围。

将自动化和数字技术整合到质量控制流程中，正成为竞争者之间的关键差异化因素，使实验室环境中的效率、准确性和合规性得以提高。西门子医疗在IVD质量控制市场中占据了显著地位，凭借其广泛的质量控制产品和解决方案，满足各种诊断应用。该公司对创新和强大研发的承诺，促成了高度准确的质量控制系统的开发，从而提升了实验室性能并确保可靠的测试结果。

西门子医疗利用其在医疗行业的良好声誉，建立在多年的经验和专业知识之上，提供先进的分析和量身定制的服务，以满足全球实验室的独特需求。

其专注于以客户为中心的解决方案和提供全面服务的能力，在竞争激烈的市场中提供了切实的优势，使医疗服务提供者能够实现最佳的运营效率和患者结果。Sysmex Corporation是IVD质量控制市场的另一主要参与者，以其在血液学和其他诊断领域的专业化而闻名。该公司将尖端技术与创新的质量控制解决方案相结合，提升实验室工作流程并确保准确的诊断结果。

Sysmex Corporation对研究和开发的强烈承诺，促成了符合国际标准的先进质量控制产品的推出，从而巩固了其在市场中的地位。

## Recent News & Developments

- **2024年第二季度：Bio-Rad推出新的InteliQ免疫测定质量控制** Bio-Rad实验室宣布推出其InteliQ免疫测定质量控制，旨在简化实验室工作流程并提高临床实验室免疫测定的准确性。
- **2024年第二季度：西门子医疗获得FDA批准Atellica解决方案质量控制模块** 西门子医疗获得FDA批准其Atellica解决方案质量控制模块，该模块自动化体外诊断测试的质量控制流程，旨在提高实验室效率和合规性。
- **2024年第二季度：罗氏推出新的多分析物质量控制面板用于分子诊断** 罗氏宣布商业推出新的多分析物质量控制面板，用于分子诊断，支持实验室确保其分子检测平台的可靠性。
- **2024年第三季度：Randox实验室在英国开设新的质量控制制造设施** Randox实验室开设了一家新的制造设施，专门生产体外诊断质量控制材料，扩大其满足全球日益增长需求的能力。
- **2024年第三季度：赛默飞世尔科技宣布与贝克曼库尔特合作开发质量控制解决方案** 赛默飞世尔科技与贝克曼库尔特达成合作，共同开发和分销先进的质量控制解决方案，旨在提高诊断准确性和工作流程。
- **2024年第三季度：Bio-Techne收购QC Diagnostics以扩展质量控制产品组合** Bio-Techne完成了对QC Diagnostics的收购，该公司专注于体外诊断的质量控制材料，以拓宽其产品供应并增强市场地位。
- **2024年第四季度：雅培获得Alinity质量控制系统的CE标志** 雅培宣布已获得Alinity质量控制系统的CE标志批准，使公司能够在欧盟市场上销售该产品，用于临床实验室。
- **2024年第四季度：QuidelOrtho推出新的点-of-care诊断质量控制软件** QuidelOrtho推出了一种新的软件平台，旨在自动化和管理其点-of-care诊断设备的质量控制流程，旨在增强合规性并减少人工错误。
- **2025年第一季度：Bio-Rad实验室任命新的质量控制部门副总裁** Bio-Rad实验室宣布任命一位新的副总裁来领导其质量控制部门，专注于体外诊断质量控制市场的战略增长和创新。
- **2025年第一季度：西门子医疗通过推出新的血液学控制扩展质量控制产品线** 西门子医疗通过推出新的血液学控制扩展其质量控制产品线，旨在支持实验室保持血液分析的高准确性标准。
- **2025年第二季度：Randox实验室获得向NHS供应质量控制材料的重要合同** Randox实验室获得了一项重要合同，向英国国家健康服务体系供应体外诊断质量控制材料，支持NHS实验室的诊断测试质量保证。
- **2025年第二季度：罗氏获得FDA批准下一代质量控制解决方案** 罗氏获得FDA批准其下一代质量控制解决方案，旨在提高临床实验室体外诊断测试的可靠性和效率。

## Report Scope

| 2024年市场规模 | 47.3（十亿美元） |
| --- | --- |
| 2025年市场规模 | 49.05（十亿美元） |
| 2035年市场规模 | 70.63（十亿美元） |
| 年复合增长率（CAGR） | 3.71%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 人工智能在IVD质量控制过程中的集成提高了准确性和效率。 |
| 主要市场动态 | 日益严格的监管审查和技术进步推动IVD质量控制市场的创新。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，IVD质量控制市场的预计市场估值是多少？**
A: 预计到2035年，IVD质量控制市场的市场估值为70.63亿美元。

**Q: 2024年IVD质量控制市场的市场估值是多少？**
A: 2024年体外诊断质量控制市场的市场估值为47.3亿美元。

**Q: 在2025年至2035年的预测期内，IVD质量控制市场的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，IVD质量控制市场的预期年均增长率（CAGR）为3.71%。

**Q: 到2035年，哪个应用领域预计将拥有最高的估值？**
A: 临床诊断应用领域预计到2035年将达到22亿美元。

**Q: IVD质量控制市场的主要产品类型有哪些？**
A: 主要产品类型包括控制血清、控制血浆、控制尿液、控制血气和控制凝血。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/in-vitro-diagnostics-quality-control-market-32725*